Precision Medicine Breakthrough: New Oral Drug Safely Slashes Triglycerides in First Human Trial

Published: January 19, 2026

For decades, the medical community has grappled with a pharmacological “catch-22” regarding liver health and heart disease. The Liver X Receptor (LXR)—a master switch for fat metabolism—offered a tempting target for lowering dangerous blood fats, yet previous attempts to flip that switch often caused unintended damage to the body’s protective cholesterol systems.

Now, a pioneering study published in Nature Medicine may have finally solved this biological puzzle. Researchers have developed an oral compound, TLC-2716, that selectively targets the liver and gut to lower triglycerides and “remnant” cholesterol without the toxic side effects that halted previous drug candidates.

In a Phase I clinical trial involving healthy adults, the drug demonstrated the ability to reduce triglycerides by nearly 40% in just two weeks. This “proof-of-concept” marks a significant milestone in the fight against hypertriglyceridemia, a condition that contributes to heart disease, stroke, and life-threatening pancreatitis.

The “Master Switch” Dilemma

Triglycerides are the most common type of fat in the body. When we consume excess calories—particularly from sugar, alcohol, and refined carbohydrates—the liver converts them into triglycerides, which are stored in fat cells for energy between meals.

However, when production outpaces the body’s ability to clear these fats, they accumulate in the bloodstream and the liver. This leads to a cascade of metabolic issues, including dyslipidemia and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as fatty liver disease.

The LXR protein acts as a regulator for genes involved in making and handling these fats. “When LXR is overactive, it drives the production of triglycerides upward,” explains Dr. Johan Auwerx of EPFL, one of the study’s lead authors. “The challenge has always been that LXR also helps maintain ‘good’ cholesterol pathways in other parts of the body. If you block it everywhere, you risk causing more harm than good.”

A Targeted Approach: The Inverse Agonist

The breakthrough lies in the drug’s precision. TLC-2716 is an inverse agonist, a sophisticated type of medication that doesn’t just block a receptor but actually prompts it to signal the opposite of its normal effect.

The research team, led by scientists at EPFL and OrsoBio, used large-scale human genetic datasets and a method called “Mendelian randomization” to confirm that a specific variant, LXRα, was the primary culprit behind elevated triglycerides. By designing TLC-2716 to remain restricted primarily to the liver and gut, they bypassed the risk of interfering with the brain or other sensitive tissues.

From Lab to Human Trials

Before testing in humans, the compound underwent rigorous validation:

• Animal Models: In rodents and non-human primates, the drug successfully lowered blood fats and reduced fat accumulation in the liver.

• Human Liver Organoids: Using “mini-livers” grown in a lab, researchers observed a significant decrease in lipid buildup, inflammation, and fibrosis (scarring).

“The data from the organoid models was particularly compelling because it showed the drug’s potential to not just lower blood fats, but to directly improve liver health at a cellular level,” says Dr. Mani Subramanian, Chief Medical Officer at OrsoBio.

Results of the Phase I Clinical Trial

The Phase I study was a randomized, placebo-controlled trial designed to test safety and tolerability in healthy volunteers over 14 days. Despite the participants starting with relatively normal lipid levels, the results were striking at higher doses:

“Remnant cholesterol”—the cholesterol found in triglyceride-rich particles—is increasingly recognized by cardiologists as a potent driver of plaque buildup in the arteries. A 61% reduction in this specific marker after eating is considered a highly significant finding for cardiovascular risk reduction.

The drug appeared to work by suppressing two specific proteins, ApoC3 and ANGPTL3, which typically act as “brakes” on the body’s fat-clearing enzymes. By lifting these brakes, TLC-2716 allowed the body to clear triglycerides more efficiently. Crucially, markers for “reverse cholesterol transport” (the body’s way of removing excess cholesterol) remained unaffected, proving the drug’s selectivity.

Expert Perspective and Limitations

Independent experts cautiously welcomed the findings. “This is a sophisticated piece of drug engineering,” says Dr. Sarah Jenkins, a cardiologist not involved in the study. “We have seen many LXR targets fail in the past due to off-target effects. The fact that this stayed liver-restricted and didn’t disrupt the ABCA1/G1 pathways is a major win.”

However, Jenkins notes that the study is still in its early stages. “While a 14-day trial in healthy volunteers is a great start, we need to see if these effects hold up over six months or a year in patients who actually have high triglycerides or established liver disease.”

Potential side effects and long-term safety remain the primary focus for the next phase of research. While the drug was well-tolerated in this short window, metabolic drugs often require long-term adherence, making safety profiles paramount.

What This Means for Patients

For those struggling with high triglycerides, current treatment often involves a combination of high-dose fish oils, fibrates, and strict lifestyle changes. However, many patients remain at “residual risk” for heart attacks even when their LDL (bad) cholesterol is well-controlled.

If TLC-2716 succeeds in Phase II and III trials, it could offer a once-daily pill that addresses the “other half” of the lipid equation—triglycerides and remnant cholesterol—which are often neglected by traditional statin therapy.

The next step for the research team is to begin Phase II trials, which will specifically recruit patients with hypertriglyceridemia and MASLD to see how the drug performs in a “real-world” clinical population.

References

Primary Study:

• Auwerx, J., Subramanian, M., et al. (2026). “An oral, liver-restricted LXRα inverse agonist for dyslipidemia: preclinical development and phase 1 trial.” Nature Medicine. DOI: 10.1038/s41591-025-04169-6.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.